Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study

被引：0
|
作者：
Kohji Shirai
Toru Fujita
Michitaka Tanaka
Yuka Fujii
Masatsugu Shimomasuda
Soichi Sakai
Yoshishige Samukawa
机构：
[1] Mihama Hospital,Department of Internal Medicine
[2] Taisho Pharmaceutical Co.,undefined
[3] Ltd.,undefined
来源：
Advances in Therapy | 2019年 / 36卷
关键词：
Body weight; Double-blind; Efficacy; Japanese; Lipase inhibitor; Obesity; Orlistat; Placebo-controlled; Randomized; Safety; Visceral fat; Waist circumference;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：86 / 100
页数：14
相关论文
共 50 条
  • [41] Safety and Efficacy of Esreboxetine in Patients With Fibromyalgia: An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
    Arnold, Lesley M.
    Chatamra, Krai
    Hirsch, Ian
    Stoker, Malcolm
    [J]. CLINICAL THERAPEUTICS, 2010, 32 (09) : 1618 - 1632
  • [42] Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial
    Liu, Shuang
    Lin, Xiaojing
    Tao, Minghao
    Chen, Qi
    Sun, Hang
    Han, Yali
    Yang, Shaoling
    Gao, Yining
    Qu, Shen
    Chen, Haibing
    [J]. LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [43] Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
    Jabbour, Serge A.
    Hardy, Elise
    Sugg, Jennifer
    Parikh, Shamik
    [J]. DIABETES CARE, 2014, 37 (03) : 740 - 750
  • [44] Efficacy and Safety of Orlistat in People with Overweight/Obese and Hyperuricemia-Results of a Randomized, Double-Blind, Placebo-Controlled Trial
    Liu, Shuang
    Qu, Shen
    Chen, Haibing
    [J]. DIABETES, 2024, 73
  • [45] Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial
    Shuang Liu
    Xiaojing Lin
    Minghao Tao
    Qi Chen
    Hang Sun
    Yali Han
    Shaoling Yang
    Yining Gao
    Shen Qu
    Haibing Chen
    [J]. Lipids in Health and Disease, 23
  • [46] Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial
    Kwak, Soo Heon
    Han, Kyung Ah
    Kim, Kyung-Soo
    Yu, Jae Myung
    Kim, EunSook
    Won, Jong Chul
    Kang, Jun Goo
    Chung, Choon Hee
    Oh, Seungjoon
    Choi, Sung Hee
    Won, Kyu Chang
    Kim, Sin Gon
    Cho, Seung Ah
    Cho, Bo Young
    Park, Kyong Soo
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1865 - 1873
  • [47] Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease - A 24-week, multicenter, double-blind, placebo-controlled study in Japan
    Homma, A
    Takeda, M
    Imai, Y
    Udaka, F
    Hasegawa, K
    Kameyama, M
    Nishimura, T
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2000, 11 (06) : 299 - 313
  • [48] Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, Randomized trial
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Ohbayashi, Toshio
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 25 (05) : 399 - 407
  • [49] Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
    Inoue, Takeshi
    Sasai, Kiyofumi
    Kitagawa, Tadayuki
    Nishimura, Akira
    Inada, Isao
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 74 (02) : 140 - 148
  • [50] Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial
    Halvorsen, Yuan-Di
    Conery, Annie L.
    Lock, John Paul
    Zhou, Wenjiong
    Freeman, Mason W.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2954 - 2962
12345